Autres langues Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
52,92 ^USD	+0,53 %		+11,89 %	+20,14 %

07/08	Scholar Rock retire un site de Novo Nordisk de sa demande de mise sur le marché pour son traitement contre la faiblesse musculaire	RE
07/08	Scholar Rock Holding confirme que l'examen de la demande de licence biologique pour l'apitegromab reste en bonne voie pour la date PDUFA du 30 septembre	MT

Autres langues

07/08	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag
07/08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date
07/08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag -- Update
06/08	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Scholar Rock Q2 Net Loss Narrows
06/08	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials
06/08	Earnings Flash (SRRK) Scholar Rock Posts Q2 Loss of $0.84 a Share, vs. FactSet Est of $0.84 Loss
06/08	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
29/07	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
20/07	Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
20/07	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
17/07	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/07	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
22/06	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
12/06	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
09/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
26/05	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
20/05	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
15/05	Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4)
15/05	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05	Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026